Tweenvest Stocks

Kailera Therapeutics, Inc. (NasdaqGS: KLRA)

Health Care · Biotechnology · US

$17.75

0.00% today · -31.7% 1Y

Kailera Therapeutics, Inc. (NasdaqGS: KLRA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.30B and employs 145 people.

Over the last twelve months the share price has lost 31.7%, trading between 16.37 and 28.23.

KLRA price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$2.30B
Revenue (TTM)
P/E
EPS
-2.25
Dividend yield
Beta (5Y)
52-week high
$28.23
52-week low
$16.37
Avg volume (3M)
Shares outstanding
129.64M
Employees
145
Next earnings

About Kailera Therapeutics, Inc.

Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.

ISIN
US4829311020
Founded
2024
Listed since
Apr 17, 2026
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$469.68B$261.53-1.60%
Amgen Inc.NasdaqGS: AMGN$239.09B$440.95-0.29%
Gilead Sciences, Inc.NasdaqGS: GILD$184.47B$147.78-0.67%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$140.13B$548.74-0.74%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$83.24B$827.02-0.78%
argenx SEENXTBR: ARGX$64.17B895.40+1.84%
Moderna, Inc.NasdaqGS: MRNA$63.41B$155.61-2.03%
CSL LimitedASX: CSL$59.49BAU$173.64+2.68%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.